Artera Raises $90 Million in Funding  

by Kay Aloha Villamor in March 23rd, 2023

Artera, a San Francisco, CA-based developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, launched publicly with $90 million in funding.

The investment comes from a syndicate of prominent tech and healthcare investors, comprised of seven institutions (Coatue, Johnson & Johnson Innovation – JJDC, Inc., Koch Disruptive Technologies, Walden Catalyst Ventures, TIME Ventures, Breyer Capital, The Factory) and 11 angel investors (Marc Benioff, Jim Breyer, Lip-Bu Tan, Chris Re, Andy Jacques, Amarjit Gill, Jeff Dean, Steve Blank, Dennis Wong, Clarence So, Michael Driscoll).

The investment will help distribute Artera's test in the U.S. and internationally and also plans to use the funding to invest in the development of tests to support personalized therapy for other cancers.

Artera’s flagship test is the ArteraAI Prostate Test, the first test to predict therapy benefits in localized prostate cancer.

“The American Cancer Society estimates that more than 288,000 new cases of prostate cancer will arise in 2023, with more than 34,000 deaths. AI has given clinicians and patients a powerful weapon in the fight against this disease,” said Andre Esteva, co-founder and CEO of Artera. “Clinicians can now leverage Artera’s unique test to prognosticate patient outcomes and personalize treatment decisions.”

Company: Artera Inc.

Raised: $90.0M

Round: Unknown

Funding Month: March 2023

Lead Investors: JJDC, Inc., Koch Disruptive Technologies, Walden Catalyst Ventures, TIME Ventures, Breyer Capital, The Factory, Marc Benioff, Jim Breyer, Lip-Bu Tan, Chris Re, Andy Jacques, Amarjit Gill, Jeff Dean, Steve Blank, Dennis Wong, Clarence So, and Michael Driscoll

Additional Investors:

Company Website: https://artera.ai/

Software Category: Medical AI Test

About the Company: Founded in 2021, Artera is a precision medicine company developing AI tests to personalize therapy for cancer patients. Their test provides risk stratification and prediction of therapeutic benefits, including the first-ever predictive test for localized prostate cancer. It is clinically available through a CLIA-certified laboratory in Jacksonville, Florida, and can be ordered online.


Source: https://www.businesswire.com/news/home/20230321005241/en/Artera-Launches-with-90-Million-in-Funding-to-Personalize-Cancer-Therapy-With-Multimodal-AI





Your cart